Denali Therapeutics Inc. - Common Stock (DNLI) stock analysis
DNLI · Denali Therapeutics Inc. - Common Stock
Latest recorded price: USD 18.08
Sector and industry: Healthcare · Biotechnology
Fiscal 2025 figures: revenue growth -100.0%, ROIC -88.2%. The model flags 1 risk signal for this company (1 high severity).
Similar companies in Healthcare
- Dianthus Therapeutics, Inc. (DNTH)
- Exelixis, Inc. - Common Stock (EXEL)
- Fortrea Holdings Inc. - Common Stock (FTRE)
- Halozyme Therapeutics, Inc. (HALO)
- Harmony Biosciences Holdings, Inc. - Common Stock (HRMY)
- ImmunityBio, Inc. (IBRX)
- IDEAYA Biosciences, Inc. - Common Stock (IDYA)
- Immunocore Holdings plc (IMCR)